Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8536248 | 0.81 | GCK (0.44) | DAO | |
| SCHEMBL18590949 | 0.77 | DAO (0.40) | DAOATAD2KDM5AHRH4MAPT | |
| SCHEMBL13469140 | 0.72 | ATAD2 (0.53) | DAOATAD2KDM5AHRH4MAPT | |
| SCHEMBL30053741 | 0.70 | KDM5A (0.50) | DAOATAD2KDM5AHRH4MAPT | |
| SCHEMBL22430460 | 0.70 | ATAD2 (0.50) | DAOATAD2KDM5AHRH4MAPT | |
| SCHEMBL23511480 | 0.67 | ATAD2 (0.47) | DAOATAD2KDM5AHRH4MAPT | |
| SCHEMBL19231060 | 0.64 | KDM4A (0.62) | DAOATAD2KDM5AKDM4AKDM4C | |
| SCHEMBL20927143 | 0.64 | DAO (0.46) | DAOATAD2KDM5AHRH4MAPT | |
| SCHEMBL17601265 | 0.62 | ATAD2 (0.60) | DAOATAD2HRH4MAPTSNCA | |
| SCHEMBL17601266 | 0.62 | ATAD2 (0.60) | DAOATAD2HRH4MAPTSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | EIF2AK2, MAVS, ZC3HAV1 | DAO 1188/4885ATAD2 2078/4885KDM5A 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.